Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jad Chahoud"'
Publikováno v:
Penile Carcinoma ISBN: 9783030820596
Recent studies have provided substantial knowledge regarding the genetic and immunological landscape for penile squamous cell carcinoma (PSCC). This new information paved the way for exploring new therapies that might be of use. This chapter will tac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0520f78dc45b9327e242526c052c4d93
https://doi.org/10.1007/978-3-030-82060-2_12
https://doi.org/10.1007/978-3-030-82060-2_12
Autor:
Ahmed Sarhan, Y. Alan Wang, Ganiraju C. Manyam, Shan Feng, Xuemin Lu, Priya Rao, Xiaoying Shang, Curtis A. Pettaway, Yanting Luo, Li Zhang, Leng Han, Jad Chahoud, Tianhe Huang, Ronald A. DePinho, Pingna Deng, Magaly Martinez Ferrer, Pheroze Tamboli, Xin Lu, Ming Guo, Xi Cheng, Yu Xiang
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Penile squamous cell carcinoma (PSCC) accounts for over 95% of penile malignancies and causes significant mortality and morbidity in developing countries. Molecular mechanisms and therapies of PSCC are understudied, owing to scarcity of laboratory mo
Autor:
Lucas Campedel, Laure Hirsch, Toni K. Choueiri, Praful Ravi, Dylan J. Martini, Omar Alhalabi, Elshad Hasanov, Ziad Bakouny, Nizar M. Tannir, Jonathan Thouvenin, Srinivas R. Viswanathan, Mehmet Asim Bilen, Philippe Barthélémy, Delphine Borchiellini, Karim Amrane, Gabriel G. Malouf, Jad Chahoud
Publikováno v:
Journal of Clinical Oncology. 39:274-274
274 Background: MiT family translocation renal cell carcinomas (TRCC) represent a rare and aggressive subgroup of RCC harboring high expression of c-MET. While response rates of VEGF receptor-tyrosine kinase inhibitor and immune checkpoint inhibitors
Autor:
Amishi Yogesh Shah, A. Zurita Saavedra, Eric Jonasch, Jad Chahoud, Andrew James Wiele, Nizar M. Tannir, Lianchun Xiao, Jeremy A. Ross, Zita Dubauskas Lim, Matthew T. Campbell
Publikováno v:
Annals of Oncology. 30:v390
Background ICI and VEGFR-targeted therapies are the primary treatments for mRCC. Len plus Eve is currently approved based on improved progression-free survival (PFS) in pts with progressive disease after one prior VEGFR-targeted therapy. However, its
Autor:
Guillermo Garcia-Manero, Jad Chahoud, Naveen Pemmaraju, Jenny Dahl, Alessandra Ferrajoli, Jovitta Jacob, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Naval Daver, Maria Khouri, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia
Publikováno v:
Blood. 126:1298-1298
Background: Patients with relapsed/refractory (R/R) ALL have limited therapeutical options. Monoclonal antibodies have shown to be effective. Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin that has shown
Autor:
Srdan Verstovsek, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Jad Chahoud, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Sherry Pierce, Musa Yilmaz, Guillermo Garcia-Manero, William G. Wierda, Nitin Jain, Koji Sasaki
Publikováno v:
Blood. 126:3722-3722
Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month
Autor:
Susan O'Brien, Deborah A. Thomas, Koji Sasaki, Guillermo Garcia-Manero, Musa Yilmaz, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Jorge E. Cortes, Rebecca Garris, Farhad Ravandi, William G. Wierda, Jad Chahoud, Haim G. Moore, Twilla Victoria Jeanis, Elias Jabbour, Alessandra Ferrajoli
Publikováno v:
Blood. 126:2496-2496
Background: Addition of tyrosine kinase inhibitors (TKIs) to chemotherapy improves outcome in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is a more potent BCR-ABL inhibitor, and covers the T315I clones. The co
Autor:
Heather M Schroeder, Guillermo Garcia-Manero, Marina Konopleva, Jad Chahoud, Paul Koller, Naval Daver, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Maria Khouri, Srdan Verstovsek, Nitin Jain, Deborah A. Thomas, Hagop M. Kantarjian, Jorge E. Cortes, Susan O'Brien, Tapan M. Kadia
Publikováno v:
Blood. 126:1295-1295
Background: The hyper-CVAD regimen is an effective frontline regimen for de novo adult ALL. Expression of CD20 was identified as an adverse prognostic factor, associated with a higher incidence of relapse, lower 3-year complete remission duration (CR